Using internal research and development capabilities, together with operational flexibility and manufacturing and regulatory expertise, SICOR
is able to take a wide variety of products from the laboratory to the worldwide market.
In the SICOR
process, once the surface is oxidized, the next step is to coat it with a graft chemical--a hydrolyzed silane--which provides a molecular "bridge" between the oxidized polymer surface and the material bonded to that surface.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company will receive final approval for fluconazole, whether the Company will successfully launch this product, whether fluconazole will receive market acceptance and those matters set forth in the risk factors section of Teva's Amendment to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on December 12, 2003, regarding Teva's acquisition of SICOR
will send a definitive proxy statement/prospectus to stockholders of record, which will contain important information about the merger with Teva.
Based upon the results of the first nine months of 2003, SICOR
believes that revenues will be in the range of US$540 million to US$550 million and diluted earnings per share in the range of US$0.
transaction significantly supports our long term strategy of profitable growth and global leadership.
(NASDAQ:SCRI), a fast-growing maker of generic injectable drugs used in anesthesiology and oncology, said earnings rose 16% to 22 cents per share.
After an exhaustive review of the available solutions, SICOR
selected I-many based upon its deep breadth of functionality and domain expertise," said Boyd Marshall, Director of Information Systems at SICOR
McDermott & Bull Executive Search and SICOR
Gensia Sicor is a wholly-owned subsidiary of SICOR
This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements including whether filgrastim will have marketing success in Lithuania, whether SICOR
will market this product in other countries and those matters set forth in the risk factors section of SICOR
's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission.
Irvine, California, September 2 /PRNewswire/ -- SICOR